Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanhua Qingjie Granules
- Development stage
- Phase 2
- Lead developer
- Fangsheng Pharmaceutical
- Administration
- Oral
01
Overview
Sanhua Qingjie Granules is a traditional Chinese medicine (TCM) granule formulation developed as a Class 1.1 innovative Chinese medicine. It is designed to disperse wind, clear heat, resolve toxicity, and benefit the throat (疏风清热、解毒利咽). The formulation is primarily indicated for the treatment of acute upper respiratory tract infections (specifically wind-heat syndrome), targeting symptoms such as fever, sore throat, cough, headache, and nasal congestion. Sanhua Qingjie Granules is composed of several herbal ingredients, with Fructus Arctii (牛蒡子) as the sovereign drug, and Flos Lonicerae Confusae (山银花), Folium Isatidis (大青叶), Herba Violae (紫花地丁), and Rhizoma Belamcandae (射干) as minister drugs, along with Herba Lygodii (海金沙藤), Radix Angelicae Dahuricae (白芷), Herba Hedyotidis Diffusae (白花蛇舌草), and Menthol (薄荷脑). It is currently in Phase II clinical development in China.
- Other names
- 三花清解颗粒
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)SLC7A1 (Cationic amino acid transporter 1)CREB1 (cAMP response element-binding protein 1)CYP7A1 (Cholesterol 7alpha-hydroxylase)DRD2 (Dopamine D2 Receptor)FABP1 (Fatty acid-binding protein 1)GLI2HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)IL10 (Interleukin-10)IL-6 (Interleukin 6)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PLTP (Phospholipid transfer protein)PPARA (Peroxisome proliferator-activated receptor alpha)FCU1 (FCU1 fusion protein)SHH (Sonic hedgehog)SMO (Smoothened)TAK1 (Transforming growth factor beta–activated kinase 1)TNFA (Tumor necrosis factor alpha (soluble))TRAF6VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Sanhua Qingjie Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanhua Qingjie Granules.